Drug intelligence / Profile preview

BAN2802

Development stage: Preclinical
Lead developer: BioArctic
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

BAN2802 is a next-generation monoclonal antibody being developed by BioArctic and Eisai for the treatment of Alzheimer's disease. It targets amyloid-beta protofibrils, similar to lecanemab, but incorporates BioArctic's proprietary BrainTransporter™ technology. This technology is designed to facilitate the active transport of the antibody across the blood-brain barrier, potentially increasing brain penetration and improving therapeutic efficacy or allowing for lower systemic dosing. As of April 2024, the drug is under a research evaluation agreement between BioArctic and Eisai, with Eisai holding an option to license the asset.

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on BAN2802.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAN2802.

Explore the full profile